Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONYX 0912 in Patients with Hematological Malignancies

ID Number 12-1673

Principal Investigator(s)
Sundar Jagannath

Department(s) or Division(s)
Hematology and Medical Oncology


Oprozomib is an investigational new drug (a drug that has not received approval by the Food and Drug Administration [FDA]) that works by preventing breakdown of proteins in cells, causing the cells to die.  Cancer cells are more susceptible to these effects than normal cells.  Oprozomib has been previously tested in approximately 79 subjects and has also been studied in animals.


The purpose of this study is to test the safety of oprozomib at different dose levels.  The researchers want to find out what effects, good and/or bad, it has on a person and their cancer.


To be able to participate in this research study a person must have been diagnosed with a hematologic malignancy.


Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: No